Adaptimmune (2014). Adaptimmune enters strategic cancer immunotherapy collaboration with GlaxoSmithKline to develop and commercialise novel cell-based therapies. Available at www.adaptimmune.com/wp-content/uploads/2014/05/Adaptimmune_GSK_-release_2-June-2014.pdf (accessed June12, 2014).
2.
Institute of Medicine (2013). Oversight and review of clinical gene transfer protocols: Assessing the role of the Recombinant DNA Advisory Committee. Available at www.nap.edu/openbook.php?record_id=18577 (accessed June12, 2014).
3.
KaiserJ. (2014). NIH will no longer require special review for U.S. gene therapy trials. ScienceInsider. Available at http://news.sciencemag.org/biology/2014/05/nih-will-no-longer-require-special-review-u.s.-gene-therapy-trials (accessed June, 12, 2014)
4.
Kite Pharma (2014a). Kite Pharma announces exclusive license with the National Institutes of Health for T cell receptor (TCR)-based products targeting NY-ESO-1 for multiple cancer indications. Available at http://kitepharma.com/c/news/releases/060614.php (accessed June12, 2014).
5.
Kite Pharma (2014b). Kite Pharma announces full exercise of underwriters' option to purchase additional shares. Available at http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=855918 (accessed June30, 2014).
6.
Lysogene (2014a). Lysogene raises a 16.5M€ Series A led by Soffinova Partners and co-led by Innobio and Novo Seeds. Available at www.lysogene.com/en/news/73-lysogene-raises-a-165-m-series-a-led-by-sofinnova-partners-and-co-led-by-innobio-and-novo-seeds (accessed June12, 2014).
7.
Lysogene (2014b). SAF-301 program. Available at www.lysogene.com/en/approach/the-saf-301-program (accessed June12, 2014).
8.
National Institutes of Health (NIH;. 2014). Statement by the NIH director on the IOM report addressing the role of the Recombinant DNA Advisory Committee in oversight of clinical gene transfer protocols. Available at www.nih.gov/about/director/05222014_statement_iom_rac.htm (accessed June12, 2014).
9.
Renaissance Capital (2014). Gene therapy biotech Vascular Biogenics files for a $75 million IPO to develop its cancer treatment. Available at www.nasdaq.com/article/gene-therapy-biotech-vascular-biogenics-files-for-a-75-million-ipo-to-develop-its-cancer-treatment-cm359911 (accessed June12, 2014).
10.
Spark Therapeutics (2014a). Spark Therapeutics raises $72.8 million in oversubscribed financing. Available at www.sparktx.com/sites/default/files/fields/press-release/spark_financing.pdf (accessed June12, 2014).
11.
Spark Therapeutics (2014b). Spark Therapeutics establishes permanent headquarters in West Philadelphia. Available at www.sparktx.com/sites/default/files/fields/press-release/new_headquarters.pdf (accessed June12, 2014).
12.
U.S. Securities and Exchange Commission (2014). Form S-1 registration statement of Kite Pharma. Available at www.sec.gov/Archives/edgar/data/1510580/000119312514204816/d705296ds1.htm (accessed June12, 2014).
13.
VBL Therapeutics (2014). Company overview. Available at www.vblrx.com/about/ (accessed June12, 2014).
